Skip to main content
Signal8

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

$INCYPress releaseMay 30, 2026, 8:00 AM ETRead the release

Incyte reported positive results from its pivotal Phase 3 frontMIND trial, showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with previously untreated, high-risk DLBCL. The combination therapy reduced the risk of disease progression or death by 25% compared to R-CHOP alone (HR 0.75, p=0.0194), with a 2-year PFS rate of 71.1% versus 62.9% for the control arm.

Key figures

Drug Name
tafasitamab (Monjuvi/Minjuvi)
Phase Of Trial
Phase 3
Os p value
0.2703
Efs p value
0.026
Pfs p value
0.0194
Os hazard ratio
0.85
Efs hazard ratio
0.79
Enrollment count
899
Pfs hazard ratio
0.75
Pfs risk reduction
25%
Pfs 2yr rate control
62.9%
Pfs 3yr rate control
60.7%
Pfs 2yr rate treatment
71.1%
Pfs 3yr rate treatment
67.3%
Median follow up months
35.2

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    INCY: Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL — AI Analysis | Signal8